JP2019511565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511565A5 JP2019511565A5 JP2018560724A JP2018560724A JP2019511565A5 JP 2019511565 A5 JP2019511565 A5 JP 2019511565A5 JP 2018560724 A JP2018560724 A JP 2018560724A JP 2018560724 A JP2018560724 A JP 2018560724A JP 2019511565 A5 JP2019511565 A5 JP 2019511565A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- immune checkpoint
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 14
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 14
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 14
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 6
- -1 cyano, carboxyl Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 5
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 102100038078 CD276 antigen Human genes 0.000 claims 3
- 101710185679 CD276 antigen Proteins 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 102000002698 KIR Receptors Human genes 0.000 claims 3
- 108010043610 KIR Receptors Proteins 0.000 claims 3
- 102000017578 LAG3 Human genes 0.000 claims 3
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 229950009795 tucaresol Drugs 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 239000012270 PD-1 inhibitor Substances 0.000 claims 1
- 239000012668 PD-1-inhibitor Substances 0.000 claims 1
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 1
- 239000012272 PD-L2 inhibitor Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229960003901 dacarbazine Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 1
- 229940121654 pd-l2 inhibitor Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 claims 1
- 229950011498 plinabulin Drugs 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063979A JP2022088662A (ja) | 2016-02-08 | 2022-04-07 | ツカレゾールまたはそのアナログを含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292763P | 2016-02-08 | 2016-02-08 | |
| US62/292,763 | 2016-02-08 | ||
| PCT/US2017/016740 WO2017139231A1 (en) | 2016-02-08 | 2017-02-06 | Compositions containing tucaresol or its analogs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063979A Division JP2022088662A (ja) | 2016-02-08 | 2022-04-07 | ツカレゾールまたはそのアナログを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019511565A JP2019511565A (ja) | 2019-04-25 |
| JP2019511565A5 true JP2019511565A5 (enExample) | 2020-03-19 |
Family
ID=59563990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560724A Pending JP2019511565A (ja) | 2016-02-08 | 2017-02-06 | ツカレゾールまたはそのアナログを含む組成物 |
| JP2022063979A Pending JP2022088662A (ja) | 2016-02-08 | 2022-04-07 | ツカレゾールまたはそのアナログを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063979A Pending JP2022088662A (ja) | 2016-02-08 | 2022-04-07 | ツカレゾールまたはそのアナログを含む組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10912748B2 (enExample) |
| EP (1) | EP3413885A4 (enExample) |
| JP (2) | JP2019511565A (enExample) |
| KR (1) | KR20180105685A (enExample) |
| CN (1) | CN108778267A (enExample) |
| AU (1) | AU2017217426B2 (enExample) |
| BR (1) | BR112018016054A2 (enExample) |
| CA (1) | CA3013467A1 (enExample) |
| CO (1) | CO2018009096A2 (enExample) |
| EC (1) | ECSP18067631A (enExample) |
| IL (1) | IL260933B2 (enExample) |
| MX (1) | MX388474B (enExample) |
| MY (1) | MY192703A (enExample) |
| NZ (1) | NZ744854A (enExample) |
| PH (1) | PH12018501669A1 (enExample) |
| RU (1) | RU2753543C1 (enExample) |
| SG (1) | SG11201806583XA (enExample) |
| WO (1) | WO2017139231A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201706281YA (en) * | 2015-02-12 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CN107530340B (zh) | 2015-03-06 | 2021-06-08 | 大连万春布林医药有限公司 | 治疗脑肿瘤的方法 |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| SG11201806583XA (en) * | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MX2019009020A (es) | 2017-02-01 | 2019-11-12 | Beyondspring Pharmaceuticals Inc | Metodo para reducir la neutropenia. |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| CN109420167B (zh) * | 2017-08-28 | 2022-02-11 | 四川九章生物科技有限公司 | 一种治疗肿瘤的联合用药物 |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| KR20210131316A (ko) | 2019-02-27 | 2021-11-02 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Sumo-활성화 효소 저해제 및 관문 저해제의 투여 |
| CA3133175A1 (en) * | 2019-03-14 | 2020-09-17 | Engene, Inc. | Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use |
| AU2020343329B2 (en) * | 2019-09-03 | 2025-07-24 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| CN112778155B (zh) * | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| JP2023524530A (ja) * | 2020-05-04 | 2023-06-12 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU190774B (en) * | 1979-06-29 | 1986-11-28 | The Wellcome Foundation Ltd,Gb | Process for preparing ether derivatives with pharmacological activity |
| HU190371B (en) * | 1980-12-18 | 1986-08-28 | The Wellcome Foundation Ltd,Gb | Process for producing ether-type compounds and pharmaceutical compositions containing them as active agents |
| AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| JPH05255106A (ja) | 1990-10-31 | 1993-10-05 | Toray Ind Inc | 血小板減少症治療剤 |
| JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| US6096786A (en) * | 1992-10-01 | 2000-08-01 | Glaxo Wellcome Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| DE69306545T2 (de) * | 1992-10-01 | 1997-04-03 | Wellcome Found | Tucaresol als Mittel zur Immunopotentierung |
| US5872151A (en) * | 1992-10-01 | 1999-02-16 | Glaxo Wellcome Inc. | Immunopotentiatory agents and physiologically acceptable salts thereof |
| PT835657E (pt) | 1992-11-27 | 2004-11-30 | Mayne Pharma Usa Inc | Composicao injectavel estavel de paclitaxel |
| JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
| US5958980A (en) * | 1993-08-26 | 1999-09-28 | Glaxo Wellcome, Inc. | Immunopotentiatory agent and physiologically acceptable salts thereof |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
| US5939098A (en) | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
| JP4070955B2 (ja) | 1997-11-21 | 2008-04-02 | ユーロ−セルティーク エス．エイ． | 置換２−アミノアセトアミドおよびその使用 |
| IL137571A0 (en) | 1998-01-29 | 2001-07-24 | Aventis Pharm Prod Inc | Method for preparing an n-[(aliphatic or aromatic)carboxyl]-2-aminoacetamide compound and a cyclyzed compound |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
| NZ506435A (en) | 1998-03-26 | 2002-08-28 | Shionogi & Co | 3-Indoly-2-hydroxy-4-oxo-2-butanoic acid useful as antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| GB9818627D0 (en) | 1998-08-26 | 1998-10-21 | Glaxo Group Ltd | Improvements in dva vaccination |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| PT1234031T (pt) | 1999-11-30 | 2017-06-26 | Mayo Foundation | B7-h1, uma nova molécula imunoregulatória |
| WO2001053290A1 (en) | 2000-01-18 | 2001-07-26 | Nippon Steel Corporation | Cell division inhibitors and process for producing the same |
| CA2403553A1 (en) * | 2000-03-17 | 2001-09-27 | David Johnson | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| US6635649B2 (en) | 2000-05-09 | 2003-10-21 | Che-Ming Teng | Piperazinedione compounds |
| JP2004518731A (ja) | 2000-12-28 | 2004-06-24 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | 三環式ｃｒｆレセプターアンタゴニスト |
| US20030082140A1 (en) | 2001-08-20 | 2003-05-01 | Fisher Paul B. | Combinatorial methods for inducing cancer cell death |
| WO2003074550A2 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
| KR20050000544A (ko) | 2002-05-17 | 2005-01-05 | 아방티 파르마 소시에테 아노님 | 유방암 및 난소암의 보조 요법에서도세탁셀/독소루비신/사이클로포스파미드의 용도 |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| IL166628A0 (en) | 2002-08-02 | 2006-01-15 | Nereus Pharmaceuticals Inc | Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
| KR101228104B1 (ko) | 2004-02-04 | 2013-02-01 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법 |
| SI1740593T1 (sl) | 2004-04-19 | 2016-08-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo polimorfne oblike I klopidogrel hidrogen sulfata |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1926724A1 (en) | 2005-09-21 | 2008-06-04 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ES2521679T3 (es) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Terapia específica usando ligandos de integrinas para el tratamiento del cáncer |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| ES2527412T3 (es) * | 2007-02-15 | 2015-01-23 | Mannkind Corporation | Método para aumentar la respuesta de los linfocitos T |
| CA2683973A1 (en) | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
| US20090170837A1 (en) | 2007-08-17 | 2009-07-02 | Thallion Pharmaceuticals Inc. | Methods for treating ras driven cancer in a subject |
| US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
| JP2011509299A (ja) | 2008-01-08 | 2011-03-24 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| EA023344B1 (ru) | 2009-01-16 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией |
| WO2010114922A1 (en) | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| HRP20150890T1 (hr) | 2009-08-10 | 2015-09-25 | Board Of Regents, The University Of Texas System | Lijeäśenje metastaza na mozgu s inhibitorima receptora endotelina u kombinaciji s citotoksiäśnim kemoterapijskim sredstvom |
| CA2774015A1 (en) | 2009-09-15 | 2011-03-24 | Cerulean Pharma Inc. | A cdp-camptothecin conjugate, particle or composition and uses thereof |
| MX2012004721A (es) * | 2009-10-23 | 2012-06-25 | Mannkind Corp | Inmunoterapia de cancer y metodo de tratamiento. |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| CN101766815B (zh) | 2009-12-31 | 2012-04-25 | 胡松华 | 紫杉醇及多西紫杉醇的用途 |
| EP2542699A4 (en) | 2010-03-03 | 2013-10-02 | Targeted Molecular Diagnostics Llc | METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION |
| WO2011146382A1 (en) | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| WO2011151423A1 (en) | 2010-06-04 | 2011-12-08 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
| WO2012035436A1 (en) | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| WO2012074904A2 (en) | 2010-11-29 | 2012-06-07 | Precision Therapeutics, Inc. | Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents |
| TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
| ES2669310T3 (es) | 2011-04-20 | 2018-05-24 | Medimmune, Llc | Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1 |
| EP2786140A4 (en) | 2011-11-28 | 2015-10-28 | Nat Res Council Canada | PACLITAXEL RESPONSE MARKERS FOR CANCER |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| KR102165348B1 (ko) | 2012-05-09 | 2020-10-14 | 캔텍스 파마슈티칼즈, 인크. | 골수억제의 치료 |
| AU2013204313C1 (en) | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| EP2958943B1 (en) | 2013-02-20 | 2019-09-11 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2968536B1 (en) | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| WO2014174480A1 (en) | 2013-04-24 | 2014-10-30 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Magnetic resonance maps for analyzing tissue |
| WO2014195852A1 (en) | 2013-06-03 | 2014-12-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor |
| MX384751B (es) | 2013-10-11 | 2025-03-14 | Beyondspring Inc | Tratamiento del cáncer con una combinación de plinabulina y taxano. |
| EA201690912A1 (ru) | 2013-11-05 | 2016-10-31 | Когнейт Биосервисис, Инк. | Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака |
| ES2738289T3 (es) | 2013-11-06 | 2020-01-21 | Hospital Clinic Barcelona | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| CN104796448B (zh) | 2014-01-22 | 2019-02-12 | 腾讯科技（深圳）有限公司 | 网络系统的数据处理方法和装置 |
| US9850225B2 (en) * | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| JP6698084B2 (ja) * | 2014-08-08 | 2020-05-27 | オンコクエスト インコーポレイテッドＯｎｃｏｑｕｅｓｔ Ｉｎｃ． | がんのチェックポイント干渉療法の成績を高めるための腫瘍抗原特異的抗体およびｔｌｒ３刺激 |
| WO2016081281A1 (en) | 2014-11-17 | 2016-05-26 | Salk Institute For Biological Studies | Lipophilic bisphosphonates and methods of use |
| SG11201706281YA (en) | 2015-02-12 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CN107530340B (zh) | 2015-03-06 | 2021-06-08 | 大连万春布林医药有限公司 | 治疗脑肿瘤的方法 |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| WO2016165007A1 (en) | 2015-04-17 | 2016-10-20 | The University Of British Columbia | Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer |
| CN106279039B (zh) | 2015-06-02 | 2019-01-11 | 青岛海洋生物医药研究院股份有限公司 | 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用 |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| EP3359692A4 (en) | 2015-10-05 | 2019-05-01 | Cedars-Sinai Medical Center | METHOD FOR CLASSIFYING AND TREATING CANCER |
| SG11201806583XA (en) * | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| JP7025416B2 (ja) | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MX2019009020A (es) | 2017-02-01 | 2019-11-12 | Beyondspring Pharmaceuticals Inc | Metodo para reducir la neutropenia. |
| BR112019018880A2 (pt) | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
| JP7350015B2 (ja) | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| BR112020015758A2 (pt) | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| CN110240592A (zh) | 2018-03-08 | 2019-09-17 | 青岛海洋生物医药研究院股份有限公司 | (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用 |
| JP7372253B2 (ja) | 2018-04-05 | 2023-10-31 | ノビガ・リサーチ・エービー | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
| KR102790127B1 (ko) | 2018-06-01 | 2025-04-03 | 비욘드스프링 파마수티컬스, 인코포레이티드. | Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법 |
| WO2020037285A1 (en) | 2018-08-16 | 2020-02-20 | Beyondspring Pharmaceuticals, Inc. | Method and composition for stimulating immune response |
| CA3119768A1 (en) | 2018-11-14 | 2020-05-22 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN112778155B (zh) | 2019-11-11 | 2023-08-11 | 大连万春布林医药有限公司 | 妥卡雷琐衍生物及其用途 |
| JP2023524530A (ja) | 2020-05-04 | 2023-06-12 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法 |
-
2017
- 2017-02-06 SG SG11201806583XA patent/SG11201806583XA/en unknown
- 2017-02-06 CA CA3013467A patent/CA3013467A1/en active Pending
- 2017-02-06 MX MX2018009413A patent/MX388474B/es unknown
- 2017-02-06 WO PCT/US2017/016740 patent/WO2017139231A1/en not_active Ceased
- 2017-02-06 EP EP17750611.0A patent/EP3413885A4/en not_active Withdrawn
- 2017-02-06 JP JP2018560724A patent/JP2019511565A/ja active Pending
- 2017-02-06 KR KR1020187024294A patent/KR20180105685A/ko not_active Ceased
- 2017-02-06 US US16/075,942 patent/US10912748B2/en active Active
- 2017-02-06 CN CN201780018762.6A patent/CN108778267A/zh active Pending
- 2017-02-06 RU RU2018128290A patent/RU2753543C1/ru active
- 2017-02-06 MY MYPI2018702720A patent/MY192703A/en unknown
- 2017-02-06 AU AU2017217426A patent/AU2017217426B2/en active Active
- 2017-02-06 BR BR112018016054-7A patent/BR112018016054A2/pt not_active Application Discontinuation
- 2017-02-06 IL IL260933A patent/IL260933B2/en unknown
- 2017-02-06 NZ NZ744854A patent/NZ744854A/en unknown
-
2018
- 2018-08-06 PH PH12018501669A patent/PH12018501669A1/en unknown
- 2018-08-29 CO CONC2018/0009096A patent/CO2018009096A2/es unknown
- 2018-09-07 EC ECSENADI201867631A patent/ECSP18067631A/es unknown
-
2021
- 2021-02-08 US US17/170,058 patent/US11857522B2/en active Active
-
2022
- 2022-04-07 JP JP2022063979A patent/JP2022088662A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511565A5 (enExample) | ||
| JP2018508572A5 (enExample) | ||
| JP2022088662A5 (enExample) | ||
| JP2021102627A5 (enExample) | ||
| IL275333B2 (en) | Inhibitors of fibroblast activation protein | |
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| JP2020111618A5 (enExample) | ||
| JP2018534329A5 (enExample) | ||
| JP2018530554A5 (enExample) | ||
| PH12019501029A1 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use therefor | |
| JP2017533266A5 (enExample) | ||
| IL266563B (en) | Heterocyclic compounds useful as pdk1 inhibitors | |
| JP2019535744A5 (enExample) | ||
| JP2019535746A5 (enExample) | ||
| JP2009514880A5 (enExample) | ||
| JP2018502902A5 (enExample) | ||
| RU2015154275A (ru) | Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf | |
| JP2016520131A5 (enExample) | ||
| JP2020532537A5 (enExample) | ||
| JP2015533176A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| JP2020536066A5 (enExample) | ||
| Hegde et al. | Systemic and targeted therapy for advanced colon cancer | |
| JP2009543771A5 (enExample) | ||
| JP2017507175A5 (enExample) |